Translating dosages from animal models to human clinical trials-revisiting body surface area scaling

FASEB Journal

Volumn 29, Issue 5, 2015, Pages 1629-1634

  Blanchard, Otis L ^a   Smoliga, James M ^b  

^a Wilmore Labs Limited Liability Company   (United States)

^b HIGH POINT UNIVERSITY   (United States)

Author keywords

Allometric scaling; Allometry; Dose conversion; Interspecies scaling; Pharmacokinetics

Indexed keywords

RESVERATROL; NEW DRUG;

ALLOMETRY; BODY SURFACE; CLINICAL TRIAL (TOPIC); DOSE CALCULATION; DRUG EFFICACY; FOOD AND DRUG ADMINISTRATION; HUMAN; MODEL; NONHUMAN; PERSONALIZED MEDICINE; PHARMACOKINETICS; PRESCRIPTION; PRIORITY JOURNAL; REVIEW; TRANSLATIONAL RESEARCH; ANIMAL; ANIMAL MODEL; DOSE RESPONSE; SPECIES DIFFERENCE; STANDARDS; THERAPEUTIC EQUIVALENCE; TISSUE DISTRIBUTION;

ANIMALIA;

ANIMALS; BODY SURFACE AREA; CLINICAL TRIALS AS TOPIC; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUGS, INVESTIGATIONAL; HUMANS; MODELS, ANIMAL; SPECIES SPECIFICITY; THERAPEUTIC EQUIVALENCY; TISSUE DISTRIBUTION;

EID: 84932645409     PISSN: 08926638     EISSN: 15306860     Source Type: Journal    
DOI: 10.1096/fj.14-269043     Document Type: Review

References (64)

1. Muller, P. Y., and Milton, M. N. (2012) The determination and interpretation of the therapeutic index in drug development. Nat. Rev. Drug Discov. 11, 751-761
2. Fan, J., and De Lannoy, I. A. (2014) Pharmacokinetics. Biochem. Pharmacol. 87, 93-120
3. Reagan-Shaw, S., Nihal, M., and Ahmad, N. (2008) Dose translation from animal to human studies revisited. FASEB J. 22, 659-661
4. Center for Drug Evaluation and Research. (2002) Guidance for Industry and Reviewers: Estimating the Safe Starting Dose in Clinical Trials for Therapeutics in Adult Healthy Volunteers, Draft Guidance, U. S. Food and Drug Administration, Rockville, MD
5. Sawyer, M., and Ratain, M. J. (2001) Body surface area as a determinant of pharmacokinetics and drug dosing. Invest. New Drugs 19, 171-177
6. Gurney, H. (2002) How to calculate the dose of chemotherapy. Br. J. Cancer 86, 1297-1302
7. Baker, S. D., Verweij, J., Rowinsky, E. K., Donehower, R. C, Schellens, J. H., Grochow, L. B., and Sparreboom, A (2002) Role of body surface area in dosing of investigational anticancer agents in adults, 1991-2001. J. Natl. Cancer Inst. 94, 1883-1888
8. Kaestner, S. A., and Sewell, G. J. (2007) Chemotherapy dosing part I: scientific basis for current practice and use of body surface area. Clin. Oncol. (R Coll Radiol) 19, 23-37
9. De Jong, M., and Maina, T. (2010) Of mice and humans: are they the same-Implications in cancer translational research. J. Nucl. Med. 51, 501-504
10. Von Bertalanffy, L. (1957) Quantitative laws in metabolism and growth. Q. Rev. Biol. 32, 217-231
11. Kleiber, M. (1947) Body size and metabolic rate. Physiol. Rev. 27, 511-541
12. Hulbert, A. (2014) A sceptics view: "Kleiber's Law" or the "3/4 Rule" is neither a law nor a rule but rather an empirical approximation. Systems 2, 186-202
13. White, C. R., and Seymour, R S. (2005) Allometric scaling of mammalian metabolism. J. Exp. Biol. 208, 1611-1619
14. Mahmood, I. (2007) Application of allometric principles for the prediction of pharmacokinetics in human and veterinary drug development. Adv. Drug Deliv. Rev. 59, 1177-1192
15. Schmidt-Nielsen, K. (1970) Energy metabolism, body size, and problems of scaling. Fed. Proc. 29, 1524-1532
16. Rubner, M. (1883) Uber den einfluss der korpergrosse auf stoffund kraftwechsel. Zeit. Biol. 19, 536-562
17. Pinkel, D. (1958) The use of body surface area as a criterion of drug dosage in cancer chemotherapy. Cancer Res. 18, 853-856
18. Dreyer, G., and Ray, W. (1910) The Blood Volume of Mammals as Determined by Experiments upon Rabbits, Guinea Pigs, and Mice and Its Relationship to the Body Weight and to the Surface Area Expressed as a Formula. Phil. Trans. Royal Soc. London, s. B. 201, 133-60
19. Dreyer, G., and Ray, W. (1912) Further Experiments upon the Blood Volume of Mammals and Its Relation to the Surface Area of the Body. Phil. Trans. Royal Soc. London, s. B. 202, 191-212
20. Kleiber, M. (1932) Body size and metabolism. Hilgardia 6, 315-353
21. Feldschuh, J., and Enson, Y. (1977) Prediction of the normal blood volume. Relation of blood volume to body habitus. Circulation 56, 605-612
22. Joslin, J. O. (2009) Blood collection techniques in exotic small mammals. J. Exot. Pet Med. 18, 117-139
23. Hoffman, R. (2013) Hematology: Basic Principles and Practice, Saunders/Elsevier, Philadelphia
24. Hough, T. A., Nolan, P. M., Tsipouri, V., Toye, A. A., Gray, I. C, Goldsworthy, M., Moir, L., Cox, R D., Clements, S., Glenister, P. H., Wood, J., Selley, R. L., Strivens, M. A., Vizor, L., McCormack, S. L., Peters, J., Fisher, E. M., Spurr, N., Rastan, S., Martin, J. E., Brown, S. D., and Hunter, A J. (2002) Novel phenotypes identified by plasma biochemical screening in the mouse. Mamm. Genome 13, 595-602
25. Zaias, J., Mineau, M., Cray, C, Yoon, D., and Altman, N. H. (2009) Reference values for serum proteins of common laboratory rodent strains. J. Am. Assoc. Lab. Anim. Sci. 48, 387-390
26. Busher, J. T. (1990) Serum albumin and globulin. In Clinical Methods: The History, Physical, and Laboratory Examinations (Walker, H. K., Hall, W. D., and Hurst, J. W., eds.), pp. 497-499, Butterworths, Boston
27. Cheval, L., Pierrat, F., Rajerison, R., Piquemal, D., and Doucet, A. (2012) Of mice and men: divergence of gene expression patterns in kidney. PLoS ONE 7, e46876
28. Al-Kahtani, M. A., Zuleta, C., Caviedes-Vidal, E., and Garland, T., Jr. (2004) Kidney mass and relative medullary thickness of rodents in relation to habitat, body size, and phylogeny. Physiol. Biochem. Zool. 77, 346-365
29. Lin, J. H. (1998) Applications and limitations of interspecies scaling and in vitro extrapolation in pharmacokinetics. Drug Metab. Dispos. 26, 1202-1212
30. Gerlowski, L. E., and Jain, R. K. (1983) Physiologically based pharmacokinetic modeling: principles and applications. J. Pharm. Sci. 72, 1103-1127
31. Center for Drug Evaluation and Research. (2005) Guidance for Industry: Estimating the Maximum Safe Starting Dose in Initial Clinical Trials for Therapeutics in Adult Healthy Volunteers, U. S. Food and Drug Administration, Rockville, MD
32. McPhee, F., Sheaffer, A K., Friborg, J., Hernandez, D., Falk, P., Zhai, G., Levine, S., Chaniewski, S., Yu, F., Barry, D., Chen, C, Lee, M. S., Mosure, K, Sun, L. Q., Sinz, M., Meanwell, N A, Colonno, R J., Knipe, J., and Scola, P. (2012) Preclinical profile and characterization of the hepatitis C virus NS3 protease inhibitor asunaprevir (BMS-650032). Antimicrob. Agents Chemother. 56, 5387-5396
33. Cirrito, J. R., Disabato, B. M., Restivo, J. L., Verges, D. K., Goebel, W. D., Sathyan, A., Hayreh, D., D'Angelo, G., Benzinger, T., Yoon, H., Kim, J., Morris, J. C, Mintun, M. A., and Sheline, Y I. (2011) Serotonin signaling is associated with lower amyloid-/3 levels and plaques in transgenic mice and humans. Proc. Natl. Acad. Sci. USA 108, 14968-14973
34. DiGiandomenico, A., Veach, R. A., Zienkiewicz, J., Moore, D. J., Wylezinski, L. S., Hutchens, M. A., and Hawiger, J. (2014) The "genomic storm" induced by bacterial endotoxin is calmed by a nuclear transport modifier that attenuates localized and systemic inflammation. PLoS ONE 9, e110183
35. Marlind, J., Kaspar, M., Trachsel, E., Sommavilla, R., Hindle, S., Bacci, C., Giovannoni, L., and Neri, D. (2008) Antibodymediated delivery of interleukin-2 to the stroma of breast cancer strongly enhances the potency of chemotherapy. Clin. Cancer Res. 14, 6515-6524
36. Suntharalingam, G., Perry, M. R., Ward, S., Brett, S. J., Castello-Cortes, A, Brunner, M. D., and Panoskaltsis, N. (2006) Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412. N Engl. J. Med. 355, 1018-1028
37. Marchetti, S., and Schellens, J. H. (2007) The impact of FDA and EMEA guidelines on drug development in relation to Phase 0 trials. Br. J. Cancer 97, 577-581
38. Mak, I. W., Evaniew, N., and Ghert, M. (2014) Lost in translation: animal models and clinical trials in cancer treatment. Am. J. Transl. Res. 6, 114-118
39. Klebovich, I., Kanerva, H., Bojti, E., Urtti, A., and Drabant, S. (1998) Comparative pharmacokinetics of deramciclane in rat, dog, rabbit and man after the administration of a single oral dose of 3 mg kg. Pharm. Pharmacol. Commun. 4, 129-136
40. Yu, R. Z., Kim, T. W., Hong, A., Watanabe, T. A., Gaus, H. J., and Geary, R. S. (2007) Cross-species pharmacokinetic comparison from mouse to man of a second-generation antisense oligonucleotide, ISIS 301012, targeting human apolipoprotein B-100. Drug Metab. Dispos. 35, 460-468
41. Mahmood, I., and Balian, J. D. (1999) The pharmacokinetic principles behind scaling from preclinical results to phase I protocols. Clin. Pharmacokinet. 36, 1-11
42. Dixon, R. L. (1976) Problems in extrapolating toxicity data for laboratory animals to man. Environ. Health Perspect. 13, 43-50
43. Schein, P. S., Davis, R. D., Carter, S., Newman, J., Schein, D. R., and Rall, D. P. (1970) The evaluation of anticancer drugs in dogs and monkeys for the prediction of qualitative toxicities in man. Clin. Pharmacol. Ther. 11, 3-40
44. Cao, X., Gibbs, S. T., Fang, L., Miller, H. A, Landowski, C. P., Shin, H. C, Lennernas, H., Zhong, Y., Amidon, G. L., Yu, L. X., and Sun, D. (2006) Why is it challenging to predict intestinal drug absorption and oral bioavailability in human using rat model. Pharm. Res. 23, 1675-1686
45. De Buck, S. S., Sinha, V. K, Fenu, L. A, Nijsen, M. J., Mackie, C. E., and Gilissen, R A (2007) Prediction of human pharma-cokinetics using physiologically based modeling: a retrospective analysis of 26 clinically tested drugs. Drug Metab. Dispos. 35, 1766-1780
46. Mahmood, I. (2005) Interspecies Pharmacokinetic Scaling: Principles and Application of Allometric Scaling, Pine House Publishers, Rockville, MD
47. Mahmood, I. (2006) Comments on "a mathematical description of the functionality of correction factors used in allometry for predicting human drug clearance". Drug Metab. Dispos. 34, 507-509
48. Atkinson, A J., Jr., and Smith, B. P. (2012) Models of physiology and physiologically based models in clinical pharmacology. Clin. Pharmacol. Ther. 92, 3-6
49. Rescigno, A. (2010) Compartmental analysis and its manifold applications to pharmacokinetics. AAPSJ. 12, 61-72
50. Parrott, N., Jones, H., Paquereau, N., and Lave, T. (2005) Application of full physiological models for pharmaceutical drug candidate selection and extrapolation of pharmacokinetics to man. Basic Clin. Pharmacol. Toxicol. 96, 193-199
51. Baur, J. A, Pearson, K J., Price, N. L., Jamieson, H. A, Lerin, C., Kalra, A., Prabhu, V. V., Allard, J. S., Lopez-Lluch, G., Lewis, K, Pistell, P. J., Poosala, S., Becker, K G., Boss, O., Gwinn, D., Wang, M., Ramaswamy, S., Fishbein, K W., Spencer, R G., Lakatta, E. G., Le Couteur, D., Shaw, R J., Navas, P., Puigserver, P., Ingram, D. K, De Cabo, R, and Sinclair, D. A (2006) Resveratrol improves health and survival of mice on a high-calorie diet. Nature 444, 337-342
52. Lagouge, M., Argmann, C, Gerhart-Hines, Z., Meziane, H., Lerin, C., Daussin, F., Messadeq, N., Milne, J., Lambert, P., Elliott, P., Geny, B., Laakso, M., Puigserver, P., and Auwerx, J. (2006) Resveratrol improves mitochondrial function and protects against metabolic disease by activating SIRT1 and PGC-1alpha. Cell 127, 1109-1122
53. Crowell, J. A., Korytko, P. J., Morrissey, R. L., Booth, T. D., and Levine, B. S. (2004) Resveratrol-associated renal toxicity. Toxicol. Sci. 82, 614-619
54. Johnson, W. D., Morrissey, R. L., Usborne, A. L., Kapetanovic, I., Crowell, J. A., Muzzio, M., and McCormick, D. L. (2011) Subchronic oral toxicity and cardiovascular safety pharmacology studies of resveratrol, a naturally occurring polyphenol with cancer preventive activity. Food Chem. Toxicol. 49, 3319-3327
55. Asensi, M., Medina, I., Ortega, A., Carretero, J., Baño, M. C., Obrador, E., and Estrela, J. M. (2002) Inhibition of cancer growth by resveratrol is related to its low bioavailability. Free Radic. Biol. Med. 33, 387-398
56. Almeida, L., Vaz-da-Silva, M., Falcão, A., Soares, E., Costa, R., Loureiro, A. I., Fernandes-Lopes, C., Rocha, J. F., Nunes, T., Wright, L., and Soares-da-Silva, P. (2009) Pharmacokinetic and safety profile of trans-resveratrol in a rising multiple-dose study in healthy volunteers. Mol. Nutr. Food Res. 53(Suppl 1), S7-S15
57. Boocock, D. J., Faust, G. E. S., Patel, K. R., Schinas, A. M., Brown, V. A., Ducharme, M. P., Booth, T. D., Crowell, J. A., Perloff, M., Gescher, A. J., Steward, W. P., and Brenner, D. E. (2007) Phase I dose escalation pharmacokinetic study in healthy volunteers of resveratrol, a potential cancer chemopreventive agent. Cancer Epidemiol. Biomarkers Prev. 16, 1246-1252
58. Walle, T., Hsieh, F., DeLegge, M. H., Oatis, J. E., Jr., and Walle, U. K. (2004) High absorption but very low bioavailability of oral resveratrol in humans. Drug Metab. Dispos. 32, 1377-1382
59. Goldberg, D. M., Yan, J., and Soleas, G. J. (2003) Absorption of three wine-related polyphenols in three different matrices by healthy subjects. Clin. Biochem. 36, 79-87
60. Meng, X., Maliakal, P., Lu, H., Lee, M. J., and Yang, C. S. (2004) Urinary and plasma levels of resveratrol and quercetin in humans, mice, and rats after ingestion of pure compounds and grape juice. J. Agric. Food Chem. 52, 935-942
61. Marier, J. F., Vachon, P., Gritsas, A., Zhang, J., Moreau, J. P., and Ducharme, M. P. (2002) Metabolism and disposition of resveratrol in rats: extent of absorption, glucuronidation, and enterohepatic recirculation evidenced by a linked-rat model. J. Pharmacol. Exp. Ther. 302, 369-373
62. Wenzel, E., and Somoza, V. (2005) Metabolism and bioavailability of trans-resveratrol. Mol. Nutr. Food Res. 49, 472-481
63. Das, S., Lin, H. S., Ho, P. C., and Ng, K. Y. (2008) The impact of aqueous solubility and dose on the pharmacokinetic profiles of resveratrol. Pharm. Res. 25, 2593-2600
64. Colom, H., Alfaras, I., Maijó, M., Juan, M. E., and Planas, J. M. (2011) Population pharmacokinetic modeling of trans-resveratrol and its glucuronide and sulfate conjugates after oral and intravenous administration in rats. Pharm. Res. 28, 1606-1621